BRIEF-Mbx Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential Pth Replacement Therapy In Chronic Hypoparathyroidism

MBX Biosciences, Inc.

MBX Biosciences, Inc.

MBX

0.00

June 12 (Reuters) - MBX Biosciences Inc MBX.O:

  • MBX BIOSCIENCES ANNOUNCES ONE-YEAR DATA DEMONSTRATING SUSTAINED BENEFIT OF ONCE-WEEKLY CANVUPARATIDE AS A POTENTIAL PTH REPLACEMENT THERAPY IN CHRONIC HYPOPARATHYROIDISM

  • MBX BIOSCIENCES - CANVUPARATIDE WELL TOLERATED WITH NO NEW SAFETY SIGNALS DURING ONE-YEAR OLE

  • MBX BIOSCIENCES - RESPONDER RATE 57% AT ONE YEAR OLE, 63% AT 12 WEEKS PHASE 2 AVAIL TRIAL

  • MBX BIOSCIENCES - PHASE 3 PIVOTAL TRIAL FOR CANVUPARATIDE ON TRACK TO INITIATE IN Q3 2026

  • MBX BIOSCIENCES - 90% OF PATIENTS IN OLE REMAINED IN STUDY AT ONE YEAR

Source text: ID:nGNX68yTP9

Further company coverage: MBX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.